Spark Prices Secondary at $47

Spark Therapeutics Announces Pricing of Public Offering

PHILADELPHIA, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $47.00 per share, before underwriting discounts. The offering consists of 2,000,000 shares being sold by Spark and 1,000,000 shares being sold by The Children’s Hospital of Philadelphia Foundation (“CHOP”), resulting in aggregate net proceeds of approximately $88.4 million to Spark and approximately $44.2 million to CHOP, after deducting underwriting discounts and before offering expenses. In addition, Spark and CHOP have granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 450,000 shares at the public offering price, less the underwriting discount. Spark will not receive any proceeds from the sale of shares by CHOP. The offering is expected to close on or about December 21, 2015, subject to satisfaction of customary closing conditions. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on December 15, 2015. J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. will act as bookrunning managers for the offering. SunTrust Robinson Humphrey, Inc. will act as lead manager and Roth Capital Partners, LLC will act as co-manager. This offering is being made only by means of a prospectus, copies of which may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by calling (631) 274-2806 or by faxing (631) 254-7140; or Evercore Group L.L.C., 55 East 52nd Street, New York, NY 10055, Attn: Prospectus Department or by telephone at (212) 849-3486. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.